Speakers
- Dr Panos Roussos MD, PhD — Icahn School of Medicine at Mount Sinai & James J. Peters VA Medical Center
- Dr Donghoon Lee PhD — Icahn School of Medicine at Mount Sinai
- Dr. Daifeng Wang — University of Wisconsin–Madison
- Georgios Voloudakis MD, PhD — Icahn School of Medicine at Mount Sinai
- Dr Kiran Girdhar PhD — Icahn School of Medicine at Mount Sinai
Abstract
The PsychAD Consortium seeks to deepen our understanding of neuropsychiatric symptoms (NPS) in Alzheimer’s disease (AD), related dementias (ADRD), and serious mental illnesses (SMIs) by exploring shared and distinct biological pathways underlying these disorders. By combining epidemiological data with advanced multi-omic and systems biology approaches, PsychAD aims to uncover biomarkers and therapeutic targets that can improve diagnosis, prognosis, and treatment of NPS.
Using a large autopsy dataset, the consortium builds high-resolution, single-cell models to examine gene expression across genetic, developmental, and disease-related dimensions. These models reveal cell-specific pathways that influence NPS and disease progression, offering valuable insights for precision medicine. Ultimately, PsychAD strives to create a foundational framework for targeted, cross-disorder treatments that address the molecular complexity of AD, ADRD, and SMIs.
Publications arising from this research are featured in a new Nature Portfolio collection, which will be highlighted during this live webinar showcasing selected findings and concluding with an audience Q&A.
Looking for more in the field?
Explore more events from Neuroscience Seminars.